Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia BioMedical Ventures in 2003 he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting